Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. It is effective in settings ranging...

Descripción completa

Detalles Bibliográficos
Autores principales: Yee, Andrew J, Raje, Noopur S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437759/
https://www.ncbi.nlm.nih.gov/pubmed/22977302
http://dx.doi.org/10.2147/CIA.S14566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437759/
https://www.ncbi.nlm.nih.gov/pubmed/22977302
http://dx.doi.org/10.2147/CIA.S14566

Ejemplares similares